BENZENO SHARON 4

Accession 0001780854-25-000002

CIK 0001478320other

View on SEC.gov Company Profile

Filed

Nov 23, 7:00 PM ET

Accepted

Nov 24, 9:39 PM ET

Size

38.5 KB

Accession

0001780854-25-000002

Insider Transaction Report

Form 4

Period: 2025-11-20

Adaptive Biotechnologies CorpADPT

BENZENO SHARON

Chief Commercial Ofc Imm Med

Transactions

Exercise/Conversion
Common Stock
2025-11-20$12.14/sh+68,961$837,187→ 594,716 total
Exercise/Conversion
Common Stock
2025-11-21$6.27/sh+834$5,229→ 297,625 total
Exercise/Conversion
Common Stock
2025-11-21$7.27/sh+34,375$249,906→ 402,314 total
Exercise/Conversion
Common Stock
2025-11-21$6.55/sh+20,834$136,463→ 318,459 total
Exercise/Conversion
Stock Option (right to buy)
2025-11-21−834→ 0 total
Exercise: $6.27Exp: 2027-04-25→ Common Stock (834 underlying)
Sale
Common Stock
2025-11-20$16.54/sh−297,925$4,927,680→ 296,791 total
Exercise/Conversion
Common Stock
2025-11-21$12.14/sh+119,809$1,454,481→ 522,123 total
Exercise/Conversion
Common Stock
2025-11-20$8.46/sh+133,032$1,125,451→ 525,755 total
Exercise/Conversion
Stock Option (right to buy)
2025-11-21−20,834→ 0 total
Exercise: $6.55Exp: 2028-02-07→ Common Stock (20,834 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-11-21−119,809→ 17,161 total
Exercise: $12.14Exp: 2032-03-04→ Common Stock (119,809 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-11-21−49,480→ 0 total
Exercise: $6.55Exp: 2028-10-01→ Common Stock (49,480 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-11-21−83,145→ 116,404 total
Exercise: $3.99Exp: 2034-03-04→ Common Stock (83,145 underlying)
Exercise/Conversion
Common Stock
2025-11-21$6.55/sh+49,480$324,094→ 367,939 total
Exercise/Conversion
Common Stock
2025-11-21$3.99/sh+83,145$331,749→ 605,268 total
Exercise/Conversion
Stock Option (right to buy)
2025-11-20−133,032→ 66,517 total
Exercise: $8.46Exp: 2033-03-06→ Common Stock (133,032 underlying)
Sale
Common Stock
2025-11-21$16.91/sh−308,477$5,216,346→ 296,791 total
Exercise/Conversion
Stock Option (right to buy)
2025-11-20−68,961→ 136,970 total
Exercise: $12.14Exp: 2032-03-04→ Common Stock (68,961 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-11-21−34,375→ 0 total
Exercise: $7.27Exp: 2029-02-07→ Common Stock (34,375 underlying)

Footnotes (10)

[F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.
[F10]The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
[F2]The options vested with respect to 1/4 of such shares on March 6, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
[F3]The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
[F4]The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
[F5]The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
[F6]The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
[F7]The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
[F8]The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
[F9]The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Documents

1 file

4
primary_doc.xmlPrimary
PRIMARY DOCUMENT

Issuer

Adaptive Biotechnologies Corp

CIK 0001478320

→

Entity typeother

Related Parties

filerCIK 0001780854

Filing Metadata

Form type: 4
Filed: Nov 23, 7:00 PM ET
Accepted: Nov 24, 9:39 PM ET
Size: 38.5 KB

View on SEC.gov